BioDelivery Sciences International reported Monday that prescriptions for its recently approved drug Bunavail increased 25 percent month-over-month during the first quarter.
Prescriptions for Bunavail, which is a treatment for opioid dependence, totaled nearly 11,000 in the quarter.
BioDelivery Sciences CEO Mark Sirgo said in a statement the company is making progress in broadening market access to the drug, noting that eight state Medicaid plans are now covering it representing more than 30,000 prescriptions per month.
“In particular, we are making significant advancements in securing manage care and pharmacy access to Bunavail,” he said.
The Raleigh company reported a first quarter net loss of $8.2 million, or 16 cents per share, compared with a loss of $4.6 million, or 11 cents per share during the same period last year.
Revenue for the quarter was $13.1 million, compared with $20.7 million during the first quarter of 2014. The company had $63.5 million cash at the end of March.
BioDelivery Sciences is also seeking regulatory approval for BEMA Buprenorphine, the company’s treatment for chronic pain. The Food and Drug Administration is expected to rule on the company’s new drug application on October 23. The treatment is being marketed under the name Belbuca.
BioDelivery shares closed Monday at $7.64, down 10 cents. The stock is down 36 percent this year.
The shares fell 24 percent in a single day in late March after BioDelivery Sciences reported disappointing results from its Phase 3 clinical trial for its treatment Clonidine Topical Gel.
Clonidine is a treatment for painful diabetic neuropathy, a condition that afflicts some people suffering from diabetes.